Moderna

IO Biotech's cancer vaccine Cylembio combined with Keytruda showed a 23% relative risk reduction in disease progression or death compared to Keytruda alone, but narrowly missed statistical significance with a p-value of 0.056.

The FDA is considering not renewing Pfizer's emergency use authorization for its COVID-19 vaccine in children aged 6 months to 4 years for the upcoming respiratory season.

Genvira Biosciences and Labskin Limited have received £1.2 million ($2.0 million) in funding through the Canada-UK Biomanufacturing of Biologics and Advanced Therapies program to develop novel melanoma immunotherapies.

Moderna plans to cut approximately 10% of its global workforce by year-end, reducing employee count from roughly 5,800 to under 5,000 as part of broader cost reduction efforts.

UNLV researchers developed ENDO (Endogenous Targeting Lipid Nanoparticles) that achieve 99% selectivity for pancreatic delivery of mRNA therapeutics via intravenous injection.

Aldevron, a Danaher-owned leader in DNA, RNA, and protein manufacturing, has opened a new Innovation Center in Waltham, Massachusetts, positioning itself at the heart of the Boston biotech corridor.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Pfizer and BioNTech's LP.8.1-adapted COMIRNATY vaccine targeting XFG and NB.1.8.1 variants.

Absci Corporation completed a $50 million public offering of 16.67 million shares at $3.00 per share to fund its AI-powered drug discovery programs and internal pipeline development.

A Turkish study of 64 patients found measurable corneal changes 75 days after receiving two doses of the Pfizer-BioNTech COVID-19 vaccine, including 2% increased thickness and 8% reduced endothelial cell density.

Moderna has canceled plans to build an mRNA vaccine manufacturing plant at Shonan Health Innovation Park in Kanagawa Prefecture due to weak global vaccine demand and challenging business conditions.